title: Antitumor effect of bevacizumab in a xenograft model of canine hemangiopericytoma.
abstract: Canine hemangiopericytoma (CHP) is characterized by frequent local recurrence and increased invasiveness. Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis in tumors. The aim of the present study was to investigate the effect of a single dose of bevacizumab on a xenograft model of CHP. VEGF protein was secreted from cultured CHP cells and interacted with bevacizumab. Bevacizumab treatment suppressed tumor growth by inhibiting tumor angiogenesis, whereas no significant differences were observed in the proliferation index and apoptosis rates of treated and untreated mice. Thus, bevacizumab had antitumor effects in a xenograft model of CHP.
authors.affiliation: Department of Veterinary Pathology, Nippon Veterinary and Life Science University, Japan. michishita@nvlu.ac.jp
authors.forename: Masaki
authors.initials: M
authors.lastname: Michishita
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Uto
authors.forename: Ryota
authors.initials: R
authors.lastname: Nakazawa
authors.forename: Hisashi
authors.initials: H
authors.lastname: Yoshimura
authors.forename: Kikumi
authors.initials: K
authors.lastname: Ogihara
authors.forename: Yuko
authors.initials: Y
authors.lastname: Naya
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Tajima
authors.forename: Daigo
authors.initials: D
authors.lastname: Azakami
authors.forename: Seigo
authors.initials: S
authors.lastname: Kishikawa
authors.forename: Toshiro
authors.initials: T
authors.lastname: Arai
authors.forename: Kimimasa
authors.initials: K
authors.lastname: Takahashi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology*; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000494:pharmacology*; D000068258:Bevacizumab; D004195:Disease Models, Animal; D004283:Dog Diseases; D004285:Dogs; D006393:Hemangiopericytoma / Q000098:blood supply* / Q000235:genetics / Q000473:pathology / Q000662:veterinary*; D008297:Male; D051379:Mice; D016688:Mice, Inbred NOD; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000235:genetics*; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab